BeiGene
BGNE
#992
Rank
C$28.36 B
Marketcap
$256.40
Share price
1.55%
Change (1 day)
5.01%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : C$3.42 Billion

According to BeiGene 's latest financial reports the company's total liabilities are C$3.42 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BeiGene - Total liabilities on balance sheet (from 2014 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31C$3.00 B11.07%
2022-12-31C$2.70 B-11.56%
2021-12-31C$3.06 B38.71%
2020-12-31C$2.20 B166.66%
2019-12-31C$0.82 B22.53%
2018-12-31C$0.67 B48.36%
2017-12-31C$0.45 B540.58%
2016-12-31C$71.09 M20.75%
2015-12-31C$58.87 M82.16%
2014-12-31C$32.32 M-39.9%
2013-12-31C$53.78 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
C$17.4 M-99.49%๐Ÿ‡บ๐Ÿ‡ธ USA
C$1.22 B-64.39%๐Ÿ‡บ๐Ÿ‡ธ USA